# **Persistent Systems**

## **SELL**

## IT Services | Q2FY26 Result Update

CMP: Rs.5,338 | TP: Rs 5,220 | Downside 2%

## Commentary turned better, though valuations remain rich

- PSYS posted Rev. of \$460mn, up 4.4% in CC terms (DE 3.9%), led by strong growth in BFSI, growing 7% QoQ, while other verticals also contributed healthily (Healthcare up 3.8%, Tech up 2.2%).
- EBIT margin rose 80bps QoQ to 16.3%, aided by +80bps from reduction in software license cost (reseller charges), +60bps FX, & +30bps offshoring; partly offset by -50bps higher doubtful debt (healthcare client), -20bps lower utilization, and -20bps higher D&A (Capex). Mgmt is confident of systemic OPM gains over FY25-FY27E.
- Healthy ACV/TCV wins (up 15% TTM basis) and a strong pipeline have led management to turn incrementally positive from its earlier cautious stance. We raise our FY26E/FY27E EPS estm by 3% each and introduce FY28E EPS at Rs.145. However, in view of overall macro-challenges, we believe valuations are full and thus maintain our 'SELL' rating with a TP of Rs 5,220 (valued at 36x FY28E EPS).

### Healthy Wins, Pipeline & Market Outlook

TCV bookings reached a record \$609mn (up 14% YoY on TTM) with new Valuation (x) bookings at \$350mn, reflecting broad-based wins across BFSI, Hi-Tech, and Healthcare. Management reports improving customer confidence and the pipelines (across segments) despite macroeconomic uncertainties. Execution capability emerges as the key differentiator, RoACE (%) positioning Persistent to capture Al-led transformation opportunities, a notably contrasting outlook versus peers' cautious recovery stance.

#### Vertical & Geographical Performance & Strategic Positioning

BFSI grew 7% QoQ/30% YoY, led by ramp-ups in large clients (F100) and expansion among Fintech players. Europe region revenue surged 7% QoQ/38% YoY on healthy momentum among Hitech clientele. Healthcare (4% QoQ/6% YoY) shows positive momentum across scientific instruments, medical devices, pharma, and payers. Management targets \$100mn quarterly revenue per sub-vertical as mentioned above in the long term (over the next 4-5 years while overall Healthcare currently stands at ~\$100mn).

#### Operating Margin Expansion & Revenue Trajectory

Management reiterated its \$2 bn revenue target by FY27 with disciplined margin expansion (200-300bps over FY25-FY27). Q2 EBIT margins improved by 80bps QoQ to 16.3% but would see Wage increments effective October, impacting margins by 180bps, which would also be offset by 80-100bps through offshoring optimization and subcontracting.



C	not Dunidana
	<u>"</u>
Bloom Code	PSYS IN
Avg. Volume (no)	5,17,898
52-Week High/Low	Rs 6,789/ 4,341
	USD 9.3bn
Market Cap	Rs 824bn
Equity / FV	Rs 779mn / Rs 10
Nifty	25,146
Key Data	

	Current	Previous
Rating	SELL	SELL
Target Price	5,220	4,730
Change in Est	imates	

(Rs.bn)	Cur	rent	Chg (%)/bps		
(179.011)	FY26E	FY27E	FY26E	FY27E	
Revenue	144	165	2.7	4.1	
EBITDA	26	30	5.6	8.4	
EBITDA (%)	18.1	18.1	49	71	
APAT	17	20	4.3	4.3	
EPS (Rs)	111.4	125.2	3.3	3.3	

	FY26E	FY27E	FY28E
P/E	47.9	42.6	36.8
EV/EBITDA	31.1	26.8	23.0
ROE (%)	25.3	24.2	23.9

26.0 24.8 24.4

Q2FY26 Result (Rs Mn)

Particulars	Q2FY26	YoY (%)	QoQ (%)
Revenue	35,807	23.6	7.4
Total Expense	28,969	19.9	6.4
EBITDA	6,838	42.2	11.8
Depreciation	1,000	34.3	6.7
EBIT	5,837	43.7	12.7
Other Income	331	17.0	(12.0)
Interest	0		
EBT	6,168	42.0	11.1
Tax	1,454	32.7	11.4
RPAT	4,715	45.1	10.9
APAT	4,715	45.1	10.9
		(bps)	(bps)
Gross Margin	36.0	258	70
EBITDA (%)	19.1	250	75
NPM (%)	13.2	195	42
Tax Rate (%)	23.6	(164)	8
EBIT (%)	16.3	228	77

**Director Research: Rahul Jain** +9122 40969771

rahuli@dolatcapital.com

Associate: Kashish Mehta +9122 40969789 kashishm@dolatcapital.com



**Exhibit 1: Quarterly performance versus estimates** 

Porticulare (Po mn)	Actual	Estima	ites	% Va	ariation	Comment	
Particulars (Rs mn)	Actual	Dolat Consensus		Dolat Consensus		Comment	
USD Revenue	406	404	397	0.6	2.4	Traction in BFSI led revenue beat	
INR Revenue	35,807	35,609	35,205	0.6	1.7		
EBIT	5,837	5,484	5,538	6.4	5.4	Large cost savings on the software	
EBIT, margin (%)	16.3	15.4	15.7	90 bps	60 bps	charge led the beat	
PAT	4,715	4,292	4,423	9.8	6.6	Better OI expanded the Beat	

Source: Company, Dolat Capital

### **Change in Estimates**

For FY26E/FY27E: Following the Q2 results, we have increased our USD rev forecasts by 1.2%/3% to positive notes of management commentary & continued healthy deal wins. We expand our OPM estm. by 30bps/37bps to account for offshoring optimization & subcontracting rationalization. We are also revising our EPS estimates upwards by 3.3% for both FY26/27E. We introduce FY28E, considering a 13% revenue growth & 30bps margin improvement, as long-term aspiration attainment efforts will support these increments.

Exhibit 2: Change in Estimates

-Xilibit 2. Olialige ili Estillates												
Particulars	FY25A		FY26E				FY28E					
(Rs. mn)	Actual	Old	New	Chg.(%)	Old	New	Chg.(%)	Introduced				
USD Revenue	1,409	1,623	1,644	1.2	1,809	1,863	3.0	2,112				
YoY growth,	18.8	15.2	16.6	144 bps	11.5	13.4	190 bps	13.4				
INR Revenue	119,387	1,40,354	1,44,162	2.7	1,58,313	1,64,880	4.1	1,88,006				
YoY growth,	21.6	17.6	20.8	319 bps	12.8	14.4	158 bps	14.0				
EBIT	17,512	21,054	22,053	4.7	23,853	25,449	6.7	29,530				
EBIT Margin,	14.7	15.0	15.3	30 bps	15.1	15.4	37 bps	15.7				
Net Profit	14,001	16,701	17,425	4.3	18,774	19,580	4.3	22,676				
EPS (Rs)	90.7	107.8	111.4	3.3	121.2	125.2	3.3	145.0				

Source: Dolat Capital, Company

### What to expect next Quarter

We expect rev growth of 2.8% QoQ in Q3FY26, driven by the continued ramp-up from healthy TCV/ACV conversions. OPM is expected to dip by  $\sim$ 159 bps QoQ due to the full-Q wage hike impact of 180bps, absence of 1x tailwinds (Software charge, Fx), though cost optimization efforts might offset some effect.

**Exhibit 3: What to expect next Quarter** 

Particulars (Rs. Mn)	Q3FY6E	Q2FY26	Q4FY25	QoQ (%)	YoY (%)
USD Revenue	418	406	360	2.8	15.9
INR Revenue	36,955	35,807	30,623	3.2	20.7
EBIT	5,438	5,837	4,557	(6.8)	19.3
PAT	4,168	4,715	3,730	(11.6)	11.8
EPS (Rs. Abs)	26.7	30.2	23.9	(11.6)	11.4
EBIT Margin (%)	14.7	16.3	14.9	(159 bps)	(17 bps)



**Exhibit 4: Key Assumptions in Our Estimates** 

Key Assumptions	FY24A	FY25A	FY26E	FY27E	FY28E
USD revenue growth (%)	14.5	18.8	16.6	13.4	13.4
INR revenue growth (%)	17.6	21.6	20.8	14.4	14.0
EBIT margin (%)	14.4	14.7	15.3	15.4	15.7
EPS growth (%)	16.7	26.2	22.8	12.4	15.8
USD/INR	82.8	84.7	87.7	88.5	89.0

Source: Company, Dolat Capital

**Exhibit 5: Key Growth Matrix** 

Growth YoY (%)	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26
USD Revenue	13.7	13.2	16.0	18.4	19.8	20.7	18.7	17.6
INR Revenue	15.2	14.9	17.9	20.1	22.6	25.2	21.8	23.6

Source: Company, Dolat Capital

**Exhibit 6: Quarterly and YTD Trend** 

Particulars (mn)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY (%)	QoQ (%)	H1FY25	H1FY26	YoY (%)
USD Revenue	346	360	375	390	406	17.6	4.2	674	796	18.1
INR Revenue	28,972	30,623	32,421	33,336	35,807	23.6	7.4	56,343	69,143	22.7
Operating Expenses	24,164	25,245	26,577	27,220	28,969	19.9	6.4	46,984	56,189	19.6
Cost of revenue	19,294	20,000	21,117	21,576	22,924	18.8	6.2	37,623	44,500	18.3
as % of sales	66.6	65.3	65.1	64.7	64.0	(258 bps)	(70 bps)	66.8	64.4	(241 bps)
SG&A expenses	4,870	5,244	5,460	5,644	6,046	24.1	7.1	9,361	11,689	24.9
as % of sales	16.8	17.1	16.8	16.9	16.9	7 bps	(5 bps)	16.6	16.9	29 bps
EBITDA	4,807	5,378	5,844	6,116	6,838	42.2	11.8	9,359	12,954	38.4
Depreciation	745	821	791	938	1,000	34.3	6.7	1,457	1,938	33.0
EBIT	4,062	4,557	5,053	5,178	5,837	43.7	12.7	7,902	11,016	39.4
Other Income	283	263	(1)	376	331	17.0	(12.0)	448	707	57.8
PBT	4,345	4,820	5,052	5,554	6,168	42.0	11.1	8,350	11,722	40.4
Total Tax	1,095	1,090	1,095	1,305	1,454	32.7	11.4	2,037	2,758	35.4
Reported PAT	3,250	3,730	3,958	4,249	4,715	45.1	10.9	6,314	8,964	42.0
Reported EPS	21.2	24.3	25.6	27.4	30.3	43.0	10.5	41.3	57.7	39.9
Margins (%)						(bps)	(bps)			(bps)
EBIDTA	16.6	17.6	18.0	18.3	19.1	250 bps	75 bps	16.6	18.7	212
EBIT	14.0	14.9	15.6	15.5	16.3	228 bps	77 bps	14.0	15.9	191
EBT	15.0	15.7	15.6	16.7	17.2	223 bps	57 bps	14.8	17.0	213
PAT	11.2	12.2	12.2	12.7	13.2	195 bps	42 bps	11.2	13.0	176
Effective Tax rate	25.2	22.6	21.7	23.5	23.6	(164 bps)	8 bps	24.4	23.5	(86)

Source: Company



### **Earning Call KTAs**

- **Revenue:** Reported revenue stood at \$406mn (up 4.4% in CC), up 4.2% QoQ and 17.6% YoY in USD terms, driven by strong momentum in BFSI, while Tech and Healthcare provided modest support to overall growth.
- **Geography:** North America led with 79.8% of revenue and steady growth of 4.2% QoQ, Europe (9% of rev) grew robustly at 7.7% QoQ driven by digital client engagements, India's (9% of rev) Geo revenues declined by 2.1% but demand strong for platform and data engineering work, and the RoW recovered & grew 26% QoQ showed healthy broad-based growth.
- Verticals: BFSI led vertical growth with a 7% QoQ increase, supported by large digital transformation projects. Software, Hi-Tech, and Emerging Industries grew 2.2%, while Healthcare & Life Sciences experienced a growth of 3.8% as it saw good demand & traction specifically in Europe.
- EBIT Margin Walkthrough: The EBIT margin for Q2FY26 improved by 80 bps sequentially to 16.3% for Q2, supported by tailwinds including 80 bps from the removal of software license costs related to a large client, which would not be incurred again, 60 bps from favorable currency movements, and 30 bps from planned offshoring. These gains were partially offset by headwinds such as a 50bps impact from higher doubtful debt provisions regarding a client in the healthcare vertical, 20 bps from lower utilization, and 20 bps due to depreciation and amortization expenses on increased facility & IT related capex.
- TCV & Deal wins: Record high TCV for Q2 was \$609mn (up ~14% YoY on TTM basis), with new bookings of \$350mn, and a pipeline supported by multi-year, Alled digital transformation deals. ACV stood at \$448mn (up ~15% YoY on TTM basis). Strategic wins included collaborations with a cloud infrastructure provider and a global energy tech firm, as well as multiple deals in BFSI, healthcare, and life sciences, highlighting continued diversification and growth in large-scale projects.
- Employees: The company increased headcount by 884 to 26,224, with attrition marginally improved to 13.8%. Wage increments were rolled out from October 1, 2025, with an expected impact of 180bps on the next quarter's margins. Wages are aligned with industry standards, and the firm continues to invest in upskilling its workforce. The current utilization level stands at 88.2% vs 88.7% QoQ, which is expected to remain in this band for the near term. Management's long-term comfort lies in the 83-85% range.
- Outlook: Management remains confident of achieving its \$2bn target in revenue by FY27, fueled by strong traction in large digital transformation deals and accelerating adoption of Al-led platform strategies. It reiterated that OPMs are projected to expand by 200–300 bps over the next two years, supported by continued investments in Al, platforms, and talent. With a robust deal pipeline, healthy renewals, and a focus on operational excellence, the company is well-positioned to sustain momentum and deliver strong, profitable growth despite some macro uncertainties.
- Al Initiatives: The Company has advanced extensively in AI, deploying over 50 internal agents across functions, winning awards and being recognized as a leader in Gartner's Generative AI quadrant. AI platform SASVA now holds 75 patents, with collaborations with Digital-Ocean and Anthropic.



**Exhibit 7: Vertical Trend for the Quarter** 

Vertical	Amount (\$ mn)	Mix (%)	QoQ (%)	YoY (%)	Incremental Revenue (\$ mn)	% Contribution of Incremental Revenue
BFSI	141	35	7.0	29.9	9	56
Tech & Emerging Vertical	162	40	2.2	15.5	3	21
Healthcare	102	25	3.8	6.6	4	23
Total	406	100	4.2	17.6	17	100

Source: Company, Dolat Capital

**Exhibit 8: Geography Trend for the Quarter** 

Geography	Amount (\$ mn)	Mix (%)	QoQ (%)	YoY (%)	Incremental Revenue (\$ mn)	% Contribution of Incremental Revenue
North America	324	80	4.2	15.4	13	80
Europe	38	9	7.7	38.4	3	16
India	37	9	(2.1)	17.6	(1)	-5
RoW	7	2	26.6	24.9	1	9
Total	406	100	4.2	17.6	17	100

Source: Company, Dolat Capital

**Exhibit 9: Client Bucket Trend the Quarter** 


Client	Amount (\$ mn)	Mix (%)	QoQ (%)	YoY (%)	Incremental Revenue (\$ mn)	% Contribution of Incremental Revenue
Top 5 client	134	33	7.8	23.2	9.7	58.9
Top 6-10 client	42	10	5.3	19.9	2.1	12.7
Top 10 Client	175	43	7.2	22.4	11.8	71.5
Non-Top 10 clients	231	57	2.1	14.2	4.7	28.5
Total	406	100	4.2	17.6	17	100.0

Source: Company, Dolat Capital

#### Valuation

We believe **PSYS** is well-positioned to deliver steady revenue growth, which should drive a healthy ~17% EPS CAGR over FY25-28E. However, the stock's current valuation of 45x on a TMF basis is still rich, trading above its 3-year median of 42.6x. This elevated multiple despite weakening macros, in our view, leaves the stock price unfavorable on a risk-reward basis. Hence, we value the stock at 36x FY28E EPS (implies over 2x on PEG basis) of Rs. 145 with revised **TP of Rs. 5,220** and **maintain our 'SELL' rating on the stock**.


Exhibit 10: PSYS trades at 44.6x TMF (near 3yr median of 42.6x), implying modest valuations






## **Story in Charts**

Exhibit 11: Rev Grew by 4.2% in \$ terms (4.4%CC)




Source: Company, Dolat Capital

Exhibit 12: OPM of 16.3%, above prev. 8Q average




Source: Company, Dolat Capital

Exhibit 13: BFSI and Healthcare led growth




Source: Company, Dolat Capital

Exhibit 14: TCV/ACV at \$609mn/\$448mn




Source: Company, Dolat Capital

Exhibit 15: Utilization at fairly high levels of 88.2%



Source: Company, Dolat Capital

Exhibit 16: Headcount saw net add. of 884





**Exhibit 17: Operating Metrics** 

Operating Metrics		Q3FY24			Q2FY25		Q4FY25	Q1FY26	Q2FY26
\$ Revenue	291.7	300.6	310.9	328.2	345.5	360.2	375.2	389.7	406.2
USD Growth, QoQ	3.1	3.0	3.4	5.6	5.3	4.3	4.2	3.9	4.2
USD Growth, YoY	14.1	13.7	13.2	16.0	18.4	19.8	20.7	18.7	17.6
Geographical Amount		-		-		-	-		
US & Canada	231.0	239.5	249.0	264.9	280.9	290.0	302.0	311.0	324.1
UK	27.7	26.7	24.2	25.6	27.3	29.5	31.5	35.1	37.8
India	28.3	30.1	31.4	32.2	31.8	33.9	34.9	38.2	37.4
RoW	4.7	4.2	6.2	5.6	5.5	6.8	6.8	5.5	6.9
Geographical YoY % Growth									
US & Canada	15.0	17.5	16.4	18.2	21.6	21.0	21.3	17.4	15.4
UK	30.6	12.4	(14.2)	(6.7)	(1.5)	10.4	30.0	37.0	38.4
India	(3.7)	(7.6)	14.4	14.8	12.3	12.7	11.1	18.7	17.6
RoW	14.1	(0.5)	25.8	64.4	18.4	62.6	8.6	(2.2)	24.9
Vertical Amount								······································	
BFSI	94.2	93.8	95.4	101.1	108.8	114.2	121.2	132.1	141.4
CMT	141.2	141.3	140.2	139.5	140.6	145.9	153.5	159.0	162.5
Healthcare	56.3	65.5	75.2	87.6	96.0	100.1	100.6	98.6	102.4
Vertical YoY % Growth									
BFSI	12.4	8.8	7.6	7.3	15.5	21.8	27.0	30.7	29.9
CMT	16.3	11.8	6.4	2.5	(0.4)	3.3	9.4	14.0	15.5
Healthcare	11.8	26.5	39.1	66.5	70.6	52.3	33.7	12.5	6.6
Top Client Amount									
Top 5 client	82.6	84.2	90.8	100.8	108.5	110.9	122.7	123.9	133.6
Top 6-10 client	32.7	34.0	33.6	35.4	34.9	33.1	35.6	39.7	41.8
Top 10 clients	115.2	118.1	124.4	136.2	143.4	144.1	158.3	163.7	175.5
Non-Top 10 clients	176.5	182.4	186.5	192.0	202.1	216.1	216.9	226.0	230.7
Top Client YoY % Growth									
Top 5 client	20.1	28.9	24.8	27.7	31.4	31.8	35.2	47.3	23.2
Top 6-10 client	30.5	24.7	12.2	7.1	6.8	(2.4)	6.2	17.0	19.9
Top 10 clients	22.9	27.7	21.1	21.6	24.4	22.0	27.3	38.6	22.4
Non-Top 10 clients	9.1	6.2	8.5	12.4	14.5	18.5	16.3	23.9	14.2
Client Engagement Size									
Large > USD 5M	39	38	40	41	43	47	55	56	56
Medium > USD 1M, < USD 5M	136	138	138	137	141	142	136	135	135
Active Billed Clients	375	375	382	374	379	383	371	NA	NA
DSO	66	66	63	67	68	64	58	56	54
Employee Data									
Technical	21,263	21,738	22,224	21,866	21,675	22,407	23,072	23,787	24,608
Sales and BD	443	465	484	510	492	489	485	496	510
Others	1,136	1,133	1,142	1,143	1,070	1,046	1,037	1,057	1,106
Total Employees	22,842	23,336	23,850	23,519	23,237	23,941	24,594	25,340	26,224
Attrition Rate (LTM)	13.5	11.9	11.5	11.9	12.0	12.6	12.9	13.9	13.8
Reported Utilization	80.6	81.5	80.0	82.1	84.8	87.4	88.1	88.7	88.2



### **Financial Performance**

### **Profit and Loss Account**

(Rs Mn)	FY25A	FY26E	FY27E	FY28E
Revenue	1,19,387	1,44,162	1,64,880	1,88,006
Total Expense	98,806	1,18,110	1,34,984	1,53,624
COGS	78,740	93,413	1,07,220	1,22,146
Employees Cost	0	0	0	0
Other expenses	20,065	24,697	27,763	31,478
EBIDTA	20,582	26,052	29,896	34,382
Depreciation	3,069	3,999	4,447	4,852
EBIT	17,512	22,053	25,449	29,530
Interest	0	0	0	0
Other Income	710	802	484	704
Exc. / E.O. items	0	0	0	0
EBT	18,223	22,855	25,934	30,235
Tax	4,221	5,430	6,354	7,559
Minority Interest	0	0	0	0
Profit/Loss share of associates	0	0	0	0
RPAT	14,001	17,425	19,580	22,676
Adjustments	0	0	0	0
APAT	14,001	17,425	19,580	22,676
Balance Sheet	FV0FA	F\/00F	FV07F	E\/00E
(Rs Mn)	FY25A	FY26E	FY27E	FY28E
Sources of Funds				
Equity Capital	779	779	779	779
Minority Interest	0	0	0	0
Reserves & Surplus	62,411	73,737	86,435	1,01,604
Net Worth	63,191	74,516	87,215	1,02,383
Total Debt	0	20	70	170
Net Deferred Tax Liability	(1,874)	(1,924)	(1,994)	(2,084)
Total Capital Employed	61,317	72,612	85,291	1,00,470
Applications of Funds				
Net Block	26,143	29,493	32,196	35,095
CWIP	42	92	117	132
Investments	9,803	9,803	9,803	9,803
Current Assets, Loans & Advances	49,354	60,727	73,748	89,317
Current Investments	0	0	0	0
Inventories	0	0	0	0
Receivables	19,142	23,572	26,413	29,509
Cash and Bank Balances	10,255	14,403	22,479	32,236
Loans and Advances	0	0	, 0	0_,0
Other Current Assets	19,957	22,752	24,856	27,573
	,	,	_ :,	,
Less: Current Liabilities & Provisions	24,025	27,503	30,574	33,877
Payables	8,886	10,493	11,971	13,553
Other Current Liabilities	15,139	17,010	18,604	20,324
sub total	-,	,	-,	-, •
Net Current Assets	25,329	33,224	43,174	55,440
Total Assets	61,317	72,612	85,291	1,00,470
F - Estimates	0.,0	,	00,201	.,,

E – Estimates



Particulars	FY25A	FY26E	FY27E	FY28E
(A) Margins (%)				
Gross Profit Margin	34.0	35.2	35.0	35.0
EBIDTA Margin	17.2	18.1	18.1	18.3
EBIT Margin	14.7	15.3	15.4	15.7
Tax rate	23.2	23.8	24.5	25.0
Net Profit Margin	11.7	12.1	11.9	12.1
(B) As Percentage of Net Sales (%)				
COGS	66.0	64.8	65.0	65.0
Employee	0.0	0.0	0.0	0.0
Other	16.8	17.1	16.8	16.7
(C) Measure of Financial Status				
Gross Debt / Equity	0.0	0.0	0.0	0.0
Interest Coverage	-			
Inventory days	0	0	0	0
Debtors days	59	60	58	57
Average Cost of Debt	0.0	0.0	0.0	0.0
Payable days	33	32	32	32
Working Capital days	46	48	46	45
FA T/O	4.6	4.9	5.1	5.4
(D) Measures of Investment				
AEPS (Rs)	90.7	111.4	125.2	145.0
CEPS (Rs)	110.6	137.0	153.6	176.0
DPS (Rs)	35.3	39.0	44.0	48.0
Dividend Payout (%)	39.0	35.0	35.1	33.1
BVPS (Rs)	409.4	476.4	557.6	654.6
RoANW (%)	24.8	25.3	24.2	23.9
RoACE (%)	25.1	26.0	24.8	24.4
RoAIC (%)	38.4	40.4	42.1	45.1
(E) Valuation Ratios				
CMP (Rs)	5338	5338	5338	5338
Mcap (Rs Mn)	8,23,898	8,23,898	8,23,898	8,23,898
EV	8,13,643	8,09,515	8,01,489	7,91,832
MCap/ Sales	6.9	5.7	5.0	4.4
EV/Sales	6.8	5.6	4.9	4.2
P/E	58.8	47.9	42.6	36.8
EV/EBITDA	39.5	31.1	26.8	23.0
P/BV	13.0	11.2	9.6	8.2
Dividend Yield (%)	0.7	0.7	0.8	0.9
(F) Growth Rate (%)				
Revenue	21.6	20.8	14.4	14.0
EBITDA	19.4	26.6	14.8	15.0
EBIT	23.8	25.9	15.4	16.0
PBT	25.9	25.4	13.5	16.6
APAT	23.9	24.5	12.4	15.8
EPS	22.1	22.8	12.4	15.8



Cash Flow				
Particulars	FY25A	FY26E	FY27E	FY28E
Profit before tax	18,223	22,855	25,934	30,235
Depreciation & w.o.	3,069	3,999	4,447	4,852
Net Interest Exp	675	(802)	(484)	(704)
Direct taxes paid	(5,114)	(5,430)	(6,354)	(7,559)
Change in Working Capital	(6,233)	(3,796)	(1,944)	(2,599)
Non Cash	950	0	0	0
(A) CF from Operating Activities	11,569	16,826	21,598	24,224
Capex {(Inc.)/ Dec. in Fixed Assets n WIP}	(2,420)	(7,400)	(7,175)	(7,765)
Free Cash Flow	9,639	9,426	14,423	16,459
(Inc)./ Dec. in Investments	(2,494)	0	0	0
Other	570	802	484	704
(B) CF from Investing Activities	(4,344)	(6,598)	(6,691)	(7,061)
Issue of Equity/ Preference	1,846	0	0	0
Inc./(Dec.) in Debt	(2,061)	20	50	100
Interest exp net	(373)	0	0	0
Dividend Paid (Incl. Tax)	(4,600)	(6,100)	(6,882)	(7,507)
Other	(1,094)	0	0	0
(C) CF from Financing	(6,282)	(6,080)	(6,832)	(7,407)
Net Change in Cash	931	4,148	8,076	9,756
Opening Cash balances	6,743	7,675	11,823	19,899
Closing Cash balances	7,675	11,823	19,899	29,656

E – Estimates

Notes



## **Stock Info and Rating History**

#### **Price Performance**

Particulars	1M	3M	12M
Absolute (%)	(1)	(5)	(5)
Rel to NIFTY (%)	(1)	(5)	(5)

### **Shareholding Pattern**

Particulars	Mar'25	Jun'25	Sep'25
Promoters	30.7	30.6	30.6
MF/Banks/FIs	26.9	27.8	30.6
FIIs	24.4	24.2	21.2
Public / Others	18.1	17.5	17.6



Month	Rating	TP (Rs.)	Price (Rs.)
Oct-24	SELL	4,250	5,158
Jan-25	SELL	4,880	5,683
Apr-25	SELL	4,760	5,164
Jul-25	SELL	4,730	5,714

\*Price as on recommendation date

Notes	



## **Dolat Rating Matrix**

Total Return Expectation (12 Months)

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

# **Dolat Team**

Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745
CONTACT DETAILS			
<b>Equity Sales</b>	Designation	E-mail	Direct Lines
Dinesh Bajaj	Director - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709
Kapil Yadav	Director - Equity Sales & Corporate Access	kapil@dolatcapital.com	+9122 4096 9735
Jubbin Shah	Director - Equity Sales	jubbins@dolatcapital.com	+9122 4096 9779
Nikhil Thacker	Director - Equity Sales	nikhilt@dolatcapital.com	+9122 4096 9773
Pratik Shroff	AVP - Equity Sales	pratiks@dolatcapital.com	+9122 4096 9621
Rajeev Lala	AVP - Equity Sales	rajeevl@dolatcapital.com	+9122 4096 9767
Equity Trading	Designation	E-mail	
P. Sridhar	Director and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728
Chandrakant Ware	Director - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707
Shirish Thakkar	Director - Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702
Kartik Mehta	Director - Sales Trading	kartikm@dolatcapital.com	+9122 4096 9715
Nishit Sariya	VP - Derivatives Sales Trading	nishits@dolatcapital.com	+9122 4096 9765
Monali Jobanputra	Co - Head Asia Derivatives	monalij@dolatcapital.com	+9122 6176 4841
Bhavin Mehta	Director Research - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705



#### Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

#### I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

#### II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited, and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. persons only: This research report is a product of Dolat Capital Market Private Limited, under Marco Polo Securities 15a-6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Research reports are intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Dolat Capital Market Private Limited has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be affected through Marco Polo or another U.S. registered broker dealer.



#### Dolat Capital Market Private Limited.

Corporate Identity Number: U65990GJ993PTC116741
Member: BSE Limited and National Stock Exchange of India Limited.
SEBI Registration No: BSE - INZ000274132, NSE - INZ000274132, Research: INH000014012

Regd. office: 1401-1409, Dalal Street Commercial, Block 53 (Bldg. No.53E) Zone-5, Road-5E, Gift City, Sector 9, Gandhinagar-382355 Gujarat, India.

Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com